News

News
19 April 2023

Genoscience Pharma has announced a new agreement for research at the Hebrew University of Jerusalem on targeted degradation technology

MARSEILLE-JERUSALEM, April 19, 2023 – Genoscience Pharma a clinical-stage biopharmaceutical company that develops disruptive therapeutics…
Read More
News
1 February 2023

ODD obtained by Genoscience Pharma from FDA to treat HCC

Genoscience Pharma receives FDA Orphan Drug Designation for ezurpimtrostat to treat HepatoCellular Carcinoma (HCC) Ezurpimtrostat…
Read More
News
6 January 2023

Genoscience Pharma announces the start of GNS561’s Phase 2b Clinical Trial

Genoscience Pharma announces launch of phase 2b clinical trial of ezurpimtrostat (GNS561) to treat hepatocarcinoma…
Read More
News
27 October 2022

Prix Galien USA 2022: Genoscience Pharma is nominated in the category “Start-up/Biotech”

Genoscience Pharma has been nominated to the Prix Galien USA 2022 A so excited event…
Read More
News
13 September 2022

Orphan Drug Designation to GNS561 for the treatment of Cholangiocarcinoma to GENFIT

Genoscience Pharma is proud that FDA granted an Orphan Drug Designation to GNS561 (a Genoscience's…
Read More
News
3 March 2022

Liver Cancer, Phase 1b Clinical results publication

Major First in Class Clinical data! Genoscience is proud to announce a new cornerstone of…
Read More
News
17 January 2022

GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition

Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed…
Read More
News
17 December 2021

GENOSCIENCE PHARMA out licenses rights of GNS561 in Europe, US and Canada territories in Cholangiocarcinoma

Genoscience is proud to announce the out-licensing of GNS561 in the cholangiocarcinoma in the United…
Read More
News
8 November 2021

GNS561, a clinical-stage PPT1 inhibitor is efficient against Hepatocarcinoma via modulation of lysosomal functions

The Genoscience Pharma's team and its collaborators are happy of this new publication in Autophagy…
Read More
News
13 September 2021

GNS561, active against Cancer Stem Cells.

A new article has been recently published in the #journalofcancer showing that #GNS561, a new #autophagy blocker, offers great…
Read More
News
Nov. 18, 2020

GNS561’s successful phase 1b trial completed

Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…
Read More
News
July 22, 2020

GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition

Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…
Read More
News
18 June, 2020

Our COVID-19 research Project supported by the French Government

Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…
Read More
News
April 6, 2020

COVID-19, GNS561’s Assault begins in France !

Marseille, April 6, 2020 — Genoscience Pharma Starts a phase 2 multicenter study using GNS561,…
Read More
News
January 13, 2020

ISO9001:2015 Certification for our R&D and Clinical Activities in Oncology

Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and…
Read More
News
December 16, 2019

GNS561 to treat pancreas or colorectal cancer with liver metastasis

GENOSCIENCE PHARMA Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or…
Read More
News
November 14, 2019

Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor

Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor to Be Presented at the…
Read More
News
September 25, 2019

Invest in the Future of Health Biotech, European Biotech Week

Invest in the Future of Health Biotech during the European Biotech Week 2019 (Brussels)  …
Read More
News
June 3, 2019

S.A.B Meeting in Chicago, during ASCO 2019

Scientific Advisory Board Meeting during ASCO 2019   Chicago, USA, June 3, 2019 — Genoscience…
Read More
News
April 17, 2019

Chaim Hurvitz, New Board of Directors Member

Chaim Hurvitz, New Board of Directors Member   Chaim Hurvitz has joined  Genoscience Pharma Board…
Read More